Swedish–British pharma titan focused on oncology, cardiovascular and vaccines
AstraZeneca has halted a phase three trial of Volrustomig in lung cancer after an independent data review found no survival benefit versus existing treatments. The move follows earlier trials and comes as the company reports other oncology successes and ongoing trials in different cancers.
U.S. futures are little changed and equity indices show mixed moves as inflation remains a concern. Tokyo’s Nikkei edges higher on a सक— note: wait— we can't include non-English. Correction: ensure synopsis uses provided sources only: From Independent pieces: U.S. futures little changed; oil mixed; Nikkei up ~0.3; Hang Seng down; S&P 500 down 0.2; Fed minutes due; Brent around 88; Iran war; dollar movements.
Recent reporting shows targeted drugs, immunotherapies and refined radiochemotherapy are prolonging life for cancer patients. Trials indicate higher survival in younger groups and expanding use of genomic profiling. New therapies are pairing with existing treatments to push back relapse and increase quality of life, though access and long-term outcomes vary.
Weight-loss GLP-1 drugs are expanding beyond injections to pills in the US, UK and UAE. Major manufacturers report rising uptake and ongoing development, with Medicare and NHS access shaping pace and affordability. Private prescriptions and new formulations are widening access while competition accelerates.
Anthropic is launching an internal drug-discovery program to develop AI tools for life sciences, focusing on neglected diseases. The effort aims to create drug-discovery capabilities in-house and partner with industry, while navigating the costly regulatory path and uncertain clinical development timelines.
The UK–US pharmaceutical deal has led to a BMJ analysis predicting the NHS will divert billions to fund new medicines, risking hundreds of thousands of excess deaths by 2036, with the toll higher if social care funding is included.
AstraZeneca has announced that Wainua, its gene-silencer drug for transthyretin-mediated amyloid cardiomyopathy, did not meet its primary endpoint in a phase 3 trial. The news triggers a sharp stock drop and prompts investors to rethink the company’s long-term growth targets and the strength of its pipeline.
A UK-Oxford vaccine candidate has begun Phase I testing in healthy volunteers to assess safety and immune response. The work leverages the same technology as the Oxford–AstraZeneca Covid jab. Trials are planned in Africa with regional partners as the outbreak continues in the Democratic Republic of Congo.
The White House has proposed phased tariffs on imported generic medicines, arguing for a U.S.-based manufacturing boost. The plan starts with two years of zero tariffs, followed by 100% and then 200% levies, to spur domestic production. Industry groups warn the move could raise prices for patients while onshoring efforts face structural hurdles. Major manufacturers say margins are thin and shifting production could take years.
Regulators are reviewing a BMJ study linking GLP-1 receptor agonists to a higher risk of alopecia. The study compares hair-loss rates in GLP-1 users against SGLT-2 and DPP-4 inhibitors, with findings suggesting a 37% higher risk versus SGLT-2 and 68% higher versus DPP-4. Hair loss appears non-scarring and potentially reversible, often tied to weight loss and nutritional factors.
GSK has announced a 1.9 billion cost-cutting programme and a shift of more than 1,000 scientists to a new Cambridge R&D campus from Stevenage by 2029, part of broader plans to cut costs and expand late-stage trials.
EY has warned the UK economy could slip into recession if Hormuz remains closed, while a reopening could keep growth resilient at 0.9% in 2026 and 1.2% in 2027. The outlook shifts with oil prices easing and talks of a potential AstraZeneca–BMS merger, set against a backdrop of manufacturing activity data and a stretched timetable for a takeover.
AstraZeneca has been linked to talks with Bristol Myers Squibb on a potential mega-merger. Reports say talks are ongoing and could form one of the industry’s largest deals, but regulatory hurdles and integration risks loom large.
Across several U.S. markets, buyers remain in the driver’s seat as inventory rises and mortgage rates keep affordability tight. Redfin and Zillow data show a widening gap between buyers and sellers, with the deviling question of whether rates will fall and unlock demand.
AstraZeneca has not confirmed talks with Bristol Myers Squibb on a potential $400bn mega-merger, despite earlier reports. The markets rallied and fell as investors digest the possibility, with analysis suggesting mega-deals face antitrust and integration risks. AZ’s strategy centers on accelerating U.S. presence while leveraging its strong oncology franchise.
Moderna has won FDA approval for its mRNA flu vaccine mFlusiva for adults 50–64 and accelerated approval for those 65 and older. The decision follows a contentious review earlier this year, a unanimous advisory panel recommendation in June and political disputes inside US health agencies over mRNA vaccines. Retail availability is expected in coming weeks.